Metagenomi Inc

(a) The Company’s landlord for its office spaces located at 5959 Horton Street, Emeryville, California (the “Premises”), Zymergen Inc. (“Zymergen”), previously filed a voluntary petition for relief under Chapter 11 of the United States Code.

In connection with this filing for relief under Chapter 11 of the United States Code, on October 3, 2023, Zymergen, its master landlord, Dynavax Technologies Corporation (“Dynavax”), and the Company entered into that certain Termination and Release Agreement dated February 22, 2024 (the “Termination Agreement”), pursuant to which the Company’s sublease agreement with Zymergen would terminate effective as of the date the conditions precedent set forth in the Termination Agreement had been satisfied. The Termination Agreement was subject to the approval of the United States Bankruptcy Court for the District of Delaware, which was obtained on February 22, 2024.

On March 7, 2024, Dynavax, as sublandlord, entered into a sublease (the “New Sublease”) with the Company, as subtenant, for the Premises, attached hereto as Exhibit 10.9. The New Sublease was subject to the consent by Dynavax’s master landlord, Emery Station West, LLC (“Emery”), which consent was received on March 7, 2024.

Under the terms of the New Sublease, which commenced on March 7, 2024, and the terms of which are substantially similar to the Company’s prior lease with Zymergen, Metagenomi will sublease the Premises from Dynavax, at the initial rental rate of $493,354 per month (the “Base Rate”), which Base Rate is subject to fifty percent (50%) abatement through June 30, 2024, as well as scheduled annual increases, all as set forth in the New Sublease. Metagenomi is also responsible for certain operating expenses and taxes throughout the term of the New Sublease. The New Sublease will continue until March 31, 2031, concurrent with the term of Dynavax’s master lease with Emery, unless sooner terminated pursuant to the terms of the New Sublease.

The New Sublease had no effect on the Company’s financial obligations.

(b) None.